1. Talimogene laherparepvec plus pembrolizumab did not significantly increase progression-free survival or overall survival compared to placebo plus pembrolizumab in ...
Click to read this study in the Journal of Clinical Oncology.
Click to read this study in Lancet Oncology.
Click to read this study in JAMA Dermatology.
Click to read this study in the Journal of Investigative Dermatology.
Click to read this study in JAMA Network Open.
1. Pathologists demonstrated high accuracy in diagnosing melanocytic lesions using the Management of Lesions to Exclude Melanoma (MOLEM) classification system ...
1. The 6.5-year progression-free survival for the nivolumab combination group, nivolumab group and in the ipilimumab group were 34%, 29% ...
1. Receiving at least 20% of infusions after 1630h was associated with decreased overall survival in patients treated with immune-checkpoint ...
Click to read the study in Clinical Cancer Research.
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.